Volume 22, Number 1—January 2016
Research
Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009–2013
Table 6
Study year | No. women | HPV 16 or 18 |
Cross-protective HPV types† |
|||||
---|---|---|---|---|---|---|---|---|
No. pos | % Pos (95% CI) | OR (95% CI) | No. pos | % Pos (95% CI) | OR (95% CI) | |||
2009 | 1,652 | 468 | 28.3 (26.2–30.6) | 1 (reference) | 211 | 12.8 (11.2–14.5) | 1 (reference) | |
2010 | 1,012 | 310 | 30.6 (27.9–33.5) | 1.13 (0.95–1.34) | 139 | 13.7 (11.8–16.0) | 1.10 (0.87–1.38) | |
2011 | 557 | 164 | 29.4 (25.8–33.4) | 1.05 (0.85–1.29) | 71 | 12.7 (10.2–15.8) | 0.99 (0.74–1.32) | |
2012 | 245 | 78 | 31.8 (26.3–37.9) | 1.18 (0.88–1.57) | 28 | 11.4 (8.0–16.0) | 0.88 (0.58–1.33) | |
2013 | 198 | 42 | 21.2 (16.1–27.4) | 0.67 (0.47–0.96) | 19 | 9.6 (6.2–14.5) | 0.71 (0.44–1.17) |
*HPV, human papillomavirus; OR, odds ratio; pos, positive.
†HPV 31, 33, or 45.
Page created: December 18, 2015
Page updated: December 18, 2015
Page reviewed: December 18, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.